Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by BridgeBio Pharma, Inc.
< Previous
1
2
Next >
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
August 08, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma Reports Second Quarter 2024 Financial Results and Business Update
August 01, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Announces Appointment of Thomas Trimarchi, Ph.D., as President and Chief Operating Officer
July 23, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
July 05, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma Surpasses Interim Analysis Enrollment Target and Receives U.S. FDA Rare Pediatric Disease Designation for BBP-418, a Potential Treatment for Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
June 18, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
June 10, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma to Participate in the 45th Annual Goldman Sachs Global Healthcare Conference
June 06, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Announces Durable Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia, and First Participant Consented in ACCEL for Hypochondroplasia
June 04, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio to Host Call on Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia on June 4, 2024
June 03, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
Additional Data Showing Acoramidis Increases Serum Transthyretin Which is Associated with Improved Cardiovascular Outcomes Presented at ISA from BridgeBio Pharma’s Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
May 29, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the 2024 ISA Meeting
May 24, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
May 15, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2024
May 14, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma Presents Additional Data and Analyses from its Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at ESC-HF, Including That Acoramidis Treatment Significantly Reduced All-Cause Mortality in a Pre-specified
May 13, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma Reports First Quarter 2024 Financial Results and Business Update
May 02, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio launches BridgeBio Oncology Therapeutics (BBOT) with $200M of private external capital to accelerate the development of its novel precision oncology pipeline
May 02, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
April 10, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
April 07, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
March 20, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma Announces Pricing of Public Offering of Common Stock
March 05, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma Announces Proposed Public Offering of Common Stock
March 04, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM
March 04, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
February 22, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma and Kyowa Kirin Announce Partnership with an Upfront Payment of $100 Million for an Exclusive License on Infigratinib in Skeletal Dysplasias in Japan
February 07, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
February 06, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma Announces U.S. Food and Drug Administration (FDA) Acceptance of New Drug Application (NDA) for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
February 05, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma Shares Positive Results of Single-Arm Phase 3 Study of Acoramidis in Japanese Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Including No Mortality Reported in the Trial at 30 Months
February 02, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma Secures up to $1.25 Billion of Capital from Blue Owl and CPP Investments to Accelerate the Development and Launch of Genetic Medicines
January 18, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma Announces Publication of Positive Results from Phase 3 ATTRibute-CM Study of Acoramidis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in the New England Journal of Medicine
January 10, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
January 10, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.